Paper Details

  1. Home
  2. Paper Details

Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis.

Author: , AbelsonMark B, BergmannMark T, GomesPaul J, GowJames A, MacejkoThomas T, McNamaraTimothy R, WilliamsJon I

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Bepotastine besilate ophthalmic solutions 1.0% and 1.5% significantly reduced ocular itching induced by conjunctival allergen challenge (CAC) for at least 8 hours, but only modestly reduced conjunctival hyperemia.
Paper Details　
Original Abstract of the Article :
PURPOSE: To evaluate the effectiveness of bepotastine besilate ophthalmic solutions 1.0% and 1.5% compared with placebo at reducing ocular itching and conjunctival hyperemia in the conjunctival allergen challenge (CAC) model of allergic conjunctivitis. DESIGN: Prospective, double-masked, randomized...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ajo.2010.02.007

データ提供：米国国立医学図書館（NLM）

Bepotastine Besilate for Allergic Conjunctivitis: A Desert Oasis for Itchy Eyes

The [treatment of allergic conjunctivitis] can feel like a journey through a sandstorm, with [itching and redness] constantly stinging the eyes. This study evaluates the effectiveness of [bepotastine besilate ophthalmic solutions] in alleviating these symptoms. The researchers employed a [prospective, double-masked, randomized, placebo-controlled, phase 3 conjunctival allergen challenge (CAC) clinical trial] to determine the efficacy and safety of the drug. The results paint a promising picture for the treatment of this common and often bothersome condition.

Bepotastine Besilate: A Promising Treatment for Itchy Eyes

The study found that [bepotastine besilate ophthalmic solutions 1.0% and 1.5%] significantly reduced [ocular itching] compared to placebo, providing relief for up to [8 hours] after application. This finding suggests that bepotastine besilate may be a valuable option for patients seeking relief from the discomfort of allergic conjunctivitis.

Navigating the Desert of Allergic Conjunctivitis

While bepotastine besilate shows promise in managing [ocular itching], it is important to remember that [allergic conjunctivitis] can be triggered by a variety of allergens. Identifying and avoiding triggers, coupled with appropriate treatment options, is crucial for maintaining eye health and comfort.

Dr.Camel's Conclusion

As a researcher who has witnessed the transformative power of medicine, I am heartened by the potential of [bepotastine besilate] to ease the suffering caused by [allergic conjunctivitis]. This study offers hope for those seeking relief from the discomfort of itchy eyes, allowing them to navigate the desert landscape of allergies with greater comfort.
Date :
  1. Date Completed 2010-07-27
  2. Date Revised 2022-03-16
Further Info :

Pubmed ID

20488431

DOI: Digital Object Identifier

10.1016/j.ajo.2010.02.007

Related Literature

Article Analysis
・Effects of bepotastine ophthalmic
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.